News und Analysen
Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US)
Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023
Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6th, at 10:00 a.m. CT
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.
Regulatory News:
Novo Nordisk A/S and BIOCORP Production SA (Paris:ALCOR) announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which
Transgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Savara to Present at the Jefferies Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023
Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Owkin Powers a New Era in Oncology Research with MOSAIC – An Unprecedented $50 Million Spatial Atlas of Cancer Cells
Owkin, Nanostring (NASDAQ:NSTG), and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum
Chemed Corporation to Present at the Jefferies 2023 Healthcare Conference
Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2023 Healthcare Conference on Thursday, June 8, 2023, at approximately 11:30 a.m. (ET) at the New
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1
Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education.
Conquer Cancer is a global community of
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F
Acadia Healthcare to Participate in Jefferies Global Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Jefferies Global Healthcare Conference, June 7-9, 2023, in New York City.
In connection
Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM Laboratory
Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSource